Business Wire

CTBC Brand Campaign Gives Gratitude to Employees

30.12.2020 04:25:00 EET | Business Wire | Press release

Share

CTBC Financial Holding Co., Ltd.'s (CTBC Financial Holding) has released a short film titled ‘A simple thank you (如常‧謝謝你)’ on Dec. 28 to express thanks to all the employees for their efforts during the COVID-19 pandemic.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201229005461/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CTBC Brand Campaign Gives Gratitude to Employees (Photo: Business Wire)

Directed by Hsiao Ya-chuan (蕭雅全) and uses “Thank You” by artist Summer Lei (雷光夏) as background music, the video restores the 91 days where more than 2,600 CTBC employees worked overtime to help 280,000 workers apply for relief loans and completed the workload that would have take two and a half years in just three months.

In response to the impacts of the COVID-19 pandemic, CTBC Financial Holding provides relief loans and has sped up the process through digital financial technology.

The filming team interviewed several employees in the hope to create realistic and detailed script for the film, and the interviewees were already in tears before they even began to talk. During the filming, more than 40 employees impressed director Hsiao with their engagement and dedication.

Chairman Wen Long Yen (顏文隆) of CTBC Financial Holding also participated in the filming this time to express his appreciation and echoed the brand sprit “We are family” with actions.

In 2001, when CTBC Bank launched a new system, thousands of employees worked overtime and sacrificed holiday to spend time with their families to make it happen. To thanks employees for their hard work, CTBC Financial Holding founder Jeffrey Koo (辜濓松) invited notable director Hou Hsiao-hsien (侯孝賢) to make a film, which was released on the New Year’s Eve in 2002, one year after the new system came online.

In 2014, a special video was made when the headquarters of CTBC relocated to CTBC Financial Park in Nangang, Taipei to express the sentiments to the old headquarters in Xinyi District.

This year, the brand campaign ‘Our Ordinary Home’ released in June presents Taiwan’s resilience in the face of the pandemic. The video has been watched more than 12 million times on the Internet.

The full-length video of “Our Ordinary Home, Thank You” is now available on YouTube and Home Run Taiwan’s Facebook fan page.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Public Relations Dept.│CTBC Bank Co., Ltd.
Name: Pamela Chen
Email: pamela.chen@ctbcbank.com
Phone: +886-2-3327-7777 Ext.6724

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye